| Business Summary | | Diversa
Corporation
develops
and
applies
proprietary
technologies
to
discover
and
evolve
novel
genes
and
gene
pathways
from
diverse
environmental
sources.
The
Company
is
utilizing
its
fully
integrated
approach
to
develop
novel
enzymes
and
other
biologically
active
compounds,
such
as
orally
active
drugs,
produced
by
these
genes
and
gene
pathways.
The
Company's
proprietary
evolution
technologies
facilitate
the
optimization
of
genes
found
in
nature
to
enable
product
solutions
for
the
pharmaceutical,
agricultural,
chemical
processing,
and
industrial
markets.
Within
these
broad
markets,
the
Company
is
targeting
key
multi-billion
dollar
market
segments
where
it
believes
its
technologies
and
products
will
create
high
value
and
competitive
advantages
for
strategic
partners
and
customers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Diversa
Corporation
is
engaged
in
discovering
and
developing
novel
enzymes
and
other
biologically
active
compounds
from
diverse
environmental
sources
for
use
in
agricultural,
chemical
processing,
industrial
and
pharmaceutical
applications.
For
the
six
months
ended
6/30/01,
total
revenue
rose
74%
to
$17
million.
Net
loss
applicable
to
Common
fell
35%
to
$4.3
million.
Results
reflect
new
and
expanded
collaborations,
partially
offset
by
higher
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Cavanaugh, Ph.D., 63 Chairman | -- | -- | Jay Short, Ph.D., 42 Pres,
CEO, Chief Technology Officer | $426K | $100K | Karin Eastham, 51 Sr.
VP- Fin., CFO and Sec. | 567K | -- | William Baum, 55 Sr.
VP- Bus. Devel. | 267K | -- | R. Patrick Simms, 56 Sr.
VP- Operations | 232K | 1.8M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|